IV: 4 to 5 g IV infusion during the first hour of treatment, followed by a continuous infusion of 1 g/hr.
Oral: 5 g orally during the first hour of treatment, followed by a continuous rate of 1 g/hr (tablets) or 1.25 g/hr (oral solution).
Duration of therapy: Usually continued for about 8 hours or until bleeding controlled.
Use: To enhance hemostasis when fibrinolysis contributes to bleeding.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice: Rapid injection of undiluted drug into a vein is not recommended.
IV compatibility: Usual compatible IV vehicles may be used (e.g., sterile water for injection, sodium chloride for Injection, 5% dextrose or Ringer's injection). The resultant solution with sterile water for injection is hypo-osmolar.
Monitoring:
Hematologic: Tests to determine the amount of fibrinolysis present.
Musculoskeletal: Creatine phosphokinase (CPK) levels in patients taking this drug long-term.
